Related Experiment Videos
Geographical variation in adverse event reporting rates in clinical trials
S Joelson1, I B Joelson, M A Wallander
1Research Laboratories, Astra Hässle AB, Mölndal, Sweden.
Pharmacoepidemiology and Drug Safety
|April 10, 2004
Summary
Adverse event reporting rates in gastro-intestinal clinical trials varied significantly across 13 countries. Patient and investigator emphasis on specific adverse events also differed by location.
Area of Science:
- Clinical pharmacology
- Gastroenterology
- Drug safety surveillance
Background:
- Clinical trials are essential for evaluating drug safety and efficacy.
- Understanding variations in adverse event reporting is crucial for global drug development.
Purpose of the Study:
- To analyze and compare adverse event reporting rates and patterns across different countries in gastro-intestinal clinical trials.
- To identify geographical variations in the reporting of general and serious adverse events.
Main Methods:
- Analysis of data from 13,698 patients across 127 gastro-intestinal clinical trials in 13 countries.
- Calculation of general and serious adverse event reporting rates and mean event counts per country.
- Qualitative assessment of adverse event reporting patterns by country.
Main Results:
- General adverse event reporting rates ranged from 17% to 68% (mean 47%); serious adverse event rates ranged from 1% to 20% (mean 8%).
- Mean reported adverse events per patient were 2.1 (range 1.5-2.7); serious adverse events were 1.4 (range 1.1-1.7).
- Significant country-specific differences observed in reporting rates, event counts, and the types of adverse events emphasized.
Conclusions:
- Substantial geographical variability exists in adverse event reporting within gastro-intestinal clinical trials.
- These variations may influence the interpretation of drug safety data and require consideration in global regulatory submissions.